Amalia Sweet has been with the Balk Lab since 2014 when she was a summer student. Having graduated from college, she is now a research assistant and hopes to go on to pursue an MD-PhD. She is broadly interested in understanding the signaling mechanisms which drive cancer progression and underlie therapeutic resistance. To this end, she is undertaking two projects to study the mechanisms of castration resistance in prostate cancer. The first of these focuses on elucidating the role of serine 81 phosphorylation in driving androgen receptor activity under castrate conditions. Secondly, she is working on establishing a mechanism for the enhanced sensitivity of enzalutamide-resistant prostate cancer cell lines to Brd4 inhibition and degradation to form a basis for novel Brd4-targeted therapy for castration resistant prostate cancer.
B.A. in Biochemistry, Smith College, Magna Cum Laude, Phi Beta Kappa